MKC 1

Next Previous
Drug Profile

MKC 1

Alternative Names: MKC-1; R 440; RO 31-7453

Latest Information Update: 18 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer CASI Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Hypoxia-inducible factor-1 alpha inhibitors; Importin beta protein inhibitors; Mitosis inhibitors; MTOR protein inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Breast cancer; Haematological malignancies; Leukaemia; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jun 2014 EntreMed is now called CASI Pharmaceuticals
  • 10 Nov 2008 MKC 1 meets primary efficacy endpoint in open-label phase I/II study in non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top